356 related articles for article (PubMed ID: 29931561)
21. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
22. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
23. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
24. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria.
Yang HK; Park MS; Choi M; Shin J; Lee SS; Jeong WK; Hwang SH; Choi SH
Abdom Radiol (NY); 2021 Nov; 46(11):5201-5217. PubMed ID: 34331549
[TBL] [Abstract][Full Text] [Related]
25. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
Park SJ; Kim JH; Joo I; Lee KB; Han JK
Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
[TBL] [Abstract][Full Text] [Related]
26. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
27. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
28. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
29. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.
Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ
J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861
[TBL] [Abstract][Full Text] [Related]
30. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion.
Park SJ; Jang S; Han JK; Kim H; Kwon W; Jang JY; Lee KB; Kim H; Lee DH
Eur Radiol; 2021 Sep; 31(9):6889-6897. PubMed ID: 33740095
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
32. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
33. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Park SJ; Kim JH; Joo I; Han JK
Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
[TBL] [Abstract][Full Text] [Related]
34. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma.
Lee JK; Kim AY; Kim PN; Lee MG; Ha HK
Eur J Radiol; 2010 Feb; 73(2):310-6. PubMed ID: 19070981
[TBL] [Abstract][Full Text] [Related]
35. Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors-Literature Review.
Gulla A; Hashimoto D; Wagner D; Damaseviciute R; Strupas K; Satoi S
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744019
[No Abstract] [Full Text] [Related]
36. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
37. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
38. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer.
Kim HW; Lee JC; Paik KH; Kang J; Kim YH; Yoon YS; Han HS; Kim J; Hwang JH
Surgery; 2017 Jun; 161(6):1579-1587. PubMed ID: 28237643
[TBL] [Abstract][Full Text] [Related]
40. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma.
Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz-Osuna S; Fabregat J
Surg Oncol; 2024 Feb; 52():102027. PubMed ID: 38113726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
